

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

27 Jul 2026

### The comparative efficacy of bupivacaine 0.5% and combination of bupivacaine 0.5% and lidocaine 2% in ultrasound guided infraclavicular block in patients with upper limb fractures: A randomized clinical trial

#### Protocol summary

##### Study aim

Comparing the efficacy of bupivacaine 0.5% and combination of bupivacaine 0.5% and lidocaine 2% in brachial plexus infraclavicular block

##### Design

A double-blind, randomized phase 2 clinical trial with parallel groups involving 80 patients. We utilized [www.Randomization.com](http://www.Randomization.com) for the randomization process.

##### Settings and conduct

This study will take place in the pain operating room at Shariati Hospital in Tehran, involving 80 patients undergoing upper limb surgery. It is a double-blind, randomized clinical trial. An anesthesia technician, not involved in the study, will prepare the medications outside the operating room. Prefilled syringes will be provided to the anesthesiologist, with all drugs being indistinguishable in color and volume. The surgeon, anesthesiologist, and patients will remain unaware of the administered drug.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: age between 18-65; body mass index (BMI) ranging from 20 to 35 kg/m<sup>2</sup> Exclusion criteria: Requiring more than one fixation in the affected limb; Allergy to opioids, acetaminophen, local anesthetics, NSAIDs; Chronic pain syndrome; Neuromascular disease; Psychological disease; drug abusers (Opioids, alcohol, other illegal drugs); chronic renal and liver disease; Loss of consciousness; pregnancy; infection at the site of procedure; Coagulation disorders or taking anticoagulant agents (except Aspirin)

##### Intervention groups

Control group: Infraclavicular block under ultrasonophy guide with 30ml bupivacaine 0.5%. Intervention group: Infraclavicular block under ultrasonophy guide with 20ml bupivacaine 0.5% and 10ml lidocaine 2%

##### Main outcome variables

Onset of complete motor and sensory block; duration of

complete motor and sensory block

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20250422065437N1**

Registration date: **2025-09-16, 1404/06/25**

Registration timing: **prospective**

Last update: **2025-09-16, 1404/06/25**

Update count: **0**

##### Registration date

2025-09-16, 1404/06/25

##### Registrant information

##### Name

Pouya Sharifi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 905 458 2517

##### Email address

pouyasrf94@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2025-09-23, 1404/07/01

##### Expected recruitment end date

2026-02-20, 1404/12/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

The comparative efficacy of bupivacaine 0.5% and combination of bupivacaine 0.5% and lidocaine 2% in ultrasound guided infraclavicular block in patients with upper limb fractures: A randomized clinical trial

**Public title**

The comparative efficacy of bupivacaine 0.5% and combination of bupivacaine 0.5% and lidocaine 2% in infraclavicular block

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Age between 18-65 Body mass index (BMI) ranging from 20 to 35 kg/m<sup>2</sup> Upper limb fracture

**Exclusion criteria:**

Requiring more than one fixation in the affected limb  
Allergy to opioids, acetaminophen, local anesthetics and nsaids  
Patients with chronic pain syndromes  
Patients abusing alcohol, opioids and other anti legal drugs  
Renal dysfunction (edema, shortness of breath, malaise, hematuria, insomnia)  
Hepatic dysfunction (jaundice, ascitis, loss of consciousness, malaise, nausea, vomiting)  
Patients with neuromuscular disease  
Patients with psychological disease  
Loss of consciousness  
Pregnancy  
Infection at the site of procedure  
Patients with coagulation disease or taking anti-coagulant agents except Aspirin  
Reluctance to participation in this study

**Age**

From **18 years** old to **65 years** old

**Gender**

Both

**Phase**

2-3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor

**Sample size**

Target sample size: **80**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Patients will be assigned to either Group A (bupivacaine 0.5%) or Group B (a combination of bupivacaine 0.5% and lidocaine 2%) through the website [www.randomization.com](http://www.randomization.com). Simple randomization will be conducted at an individualized level. After randomization, the results will be placed in concealed, opaque envelopes. An anesthesiology technician who is not involved in this study and is responsible for drug preparation will open these envelopes. The technician will prepare the drug outside of the operation room and prefilled syringes will be given to anesthesiologist. The prepared drugs are similar in term of the color and volume. The surgeon, patients, and anesthesiologist will

remain blinded to the drugs used in the study.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

After randomization, the results will be placed in concealed, opaque envelopes. An anesthesiology technician who is not involved in this study and is responsible for drug preparation will open these envelopes. The technician will prepare the drug outside of the operation room and prefilled syringes will be given to anesthesiologist. The prepared drugs are similar in term of the color and volume. The surgeon, patients, and anesthesiologist will remain blinded to the drugs used in the study.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Tehran University of Medical Sciences

**Street address**

Shariati hospital, the intersection of South Kargar street and Jalal-e-Aal-e- Ahmad boulevard

**City**

Tehran

**Province**

Tehran

**Postal code**

1411713135

**Approval date**

2024-02-13, 1402/11/24

**Ethics committee reference number**

IR.TUMS.SHARIATI.REC.1403.117

**Health conditions studied****1****Description of health condition studied**

Upper limb fractures

**ICD-10 code**

T10

**ICD-10 code description**

Fracture of upper limb, level unspecified

**Primary outcomes****1****Description**

Onset of complete sensory block

**Timepoint**  
Every 1 minute up to 10 minutes, every 2 minutes up to 10 minutes and then every 5 minutes up to 10 minutes or complete anesthesia

**Method of measurement**  
Hollman scale with pinprick test

## 2

**Description**  
Onset of complete motor block

**Timepoint**  
Every 5 minutes up to 30 minutes

**Method of measurement**  
Physical examination of thumb abduction (radial nerve), third finger flexion (median nerve), fifth finger flexion (ulnar nerve) and elbow flexion (musculocutaneous)

## Secondary outcomes

### 1

**Description**  
Duration of sensory block

**Timepoint**  
Every 5 minutes after the onset of complete sensory block

**Method of measurement**  
Time between the onset of complete sensory block to first sensation of pain or patient request for painkillers.

### 2

**Description**  
Duration of motor block

**Timepoint**  
Every 5 minutes after the onset of complete motor block

**Method of measurement**  
Time between the onset of complete motor block to return of finger functions (Grade 2 in Hollmen Scale)

## Intervention groups

### 1

**Description**  
Control group: Ultrasonography probe will be placed medial to coracoid and in a sagittal plane. After visualizing the medial, lateral and posterior cord around the axillary artery, a 18 G, 10Cm needle will be inserted 1 cm medial to coracoid and 10 cm below the clavicle. After infiltration of 1ml Lidocaine 2%, 30 ml of bupivacaine 0.5% will be injected around the medial, lateral and posterior cords.

**Category**  
Treatment - Other

### 2

**Description**  
Intervention group: Ultrasonography probe will be placed

medial to coracoid and in a sagittal plane. After visualizing the medial, lateral and posterior cord around the axillary artery, a 18 G, 10Cm needle will be inserted 1 cm medial to coracoid and 10 cm below the clavicle. After infiltration of 1ml Lidocaine 2%, 30 ml of bupivacaine 0.5% in combination with 10 ml of Lidocaine 2% will be injected around the medial, lateral and posterior cords.

**Category**  
Treatment - Other

## Recruitment centers

### 1

**Recruitment center**  
**Name of recruitment center**  
Shariati hospital  
**Full name of responsible person**  
Pouya Sharifi  
**Street address**  
Shariati hospital, the intersection of South Kargar street and Jalal-e-Aal-e- Ahmad boulevard  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1411713135  
**Phone**  
+98 911 458 2017  
**Email**  
pouya.srf94@gmail.com

## Sponsors / Funding sources

### 1

**Sponsor**  
**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**  
Dr Ahmadreza Jamshidi  
**Street address**  
Shariati hospital, the intersection of South Kargar street and Jalal-e-Aal-e- Ahmad boulevard  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1411713135  
**Phone**  
+98 911 458 2017  
**Email**  
pouya.srf94@gmail.com  
**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**

Tehran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Pouya Sharifi

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Anesthesiology

**Street address**

No 6, Mokhtari avenue, Khojastepoor street, Bagh

Feiz

**City**

Tehran

**Province**

Tehran

**Postal code**

1114713135

**Phone**

+98 905 458 2517

**Fax**

**Email**

pouyasrf94@gmail.com

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Pouya Sharifi

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Anesthesiology

**Street address**

No 6, Mokhtari avenue, Khojastepoor street, Bagh

Feiz

**City**

Tehran

**Province**

Tehran

**Postal code**

1114713135

**Phone**

+98 905 458 2517

**Fax**

**Email**

pouyasrf94@gmail.com

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Pouya Sharifi

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Anesthesiology

**Street address**

No 6, Mokhtari avenue, Khojastepoor street, Bagh

Feiz

**City**

Tehran

**Province**

Tehran

**Postal code**

1114713135

**Phone**

+98 905 458 2517

**Fax**

**Email**

pouyasrf94@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

All collected deidentified IPD

**When the data will become available and for how long**

6 months after publication of the paper

**To whom data/document is available**

People working in academic institutions

**Under which criteria data/document could be used**

The analyzed data can only be used in purpose of designing similar studies or review articles.

**From where data/document is obtainable**

Dr Pouya Sharifi; 00989114582017

pouya.srf94@gmail.com

**What processes are involved for a request to access data/document**

Please send your request via SMS or Email to Dr Sharifi.

The information will be available in 1 or 2 weeks.

**Comments**